Pharmacokinetic and Pharmacodynamic Evaluation of Topical TAR-0520 Gel for Mitigating Adverse Reactions in Anticancer Therapy

The primary objective of this study is to evaluate the **local tolerance** and pharmacokinetics/pharmacodynamics (**PK/PD**) of TAR-0520 gel when applied topically in healthy subjects. This is clinically relevant as it aims to assess the safety and systemic exposure of the gel, which is intended for the prevention of adverse reactions associated with anticancer therapy. Understanding the local tolerance and PK/PD profile is crucial for determining the potential of TAR-0520 gel to mitigate side effects in patients undergoing cancer treatment.

The clinical trial focuses on the **prevention of anticancer therapy adverse reactions** and includes both male and female participants. The study population encompasses adults aged 18 to 65 years, representing a broad age range. Participants are selected without targeting any vulnerable populations, ensuring a general representation of the adult demographic. The sponsor has not provided information regarding the total number of participants involved in the trial. The selection process does not emphasize specific lifestyle considerations such as diet, physical activity, or habits, allowing for a diverse participant pool. The trial does not specify any key inclusion or exclusion criteria, indicating a potentially wide eligibility for participation.

The clinical trial is designed to evaluate the **local tolerance** and pharmacokinetics/pharmacodynamics (PK/PD) of TAR-0520 gel when applied topically in healthy subjects. This study is a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the prevention of adverse reactions associated with anticancer therapy. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on September 18, 2023, to the anticipated end date on June 1, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized and commence the treatment phase. Throughout the trial, follow-up visits will be scheduled to monitor the safety and efficacy of the treatment, as well as to collect necessary PK/PD data. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement is aligned with the trial's duration, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's methodology and design are structured to ensure the collection of robust data while maintaining participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Furthermore, the documentation lacks information on **participant compliance monitoring** and any additional relevant details about drug administration or dosing schedules. The absence of these details limits the ability to provide a comprehensive description of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on September 18, 2023, with an estimated end date of June 1, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy will be aligned with the standard practices of Phase 3 clinical trials, which typically involve rigorous testing to confirm the effectiveness of the intervention under investigation.